The Ledger
Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.
why aren't all 9 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable
Kaganovich: Genetics companies build clinical DNA tests using unmanaged public FTPs
“Every genetics company, every hospital, they design and implement tests To figure out what disease you have, or don't have, or whether you should have a child, or what drug to take based on your DNA. They use this data that's collected by academics and deposit…”
Kaganovich: Most people derive no actionable information from genome sequencing
“For most people, there's no information that they glean yet from it.”
Kaganovich: Human genome sequencing costs plummeted from $3 billion to $1,000
“This thing can sequence your genome for a thousand dollars, and it, 10 years ago, cost, like, three billion, and was really hard.”
Kaganovich: Public academic genomic databases lack quality control and version tracking
“It's great data for the first, kind of, chapter one of genetics, but the problem is that there's no quality control. You don't know what, which records are right, which records aren't relevant. There's no feedback for this worked for me, this didn't work for m…”
Kaganovich predicts multi-billion dollar companies will emerge around DNA variant measurement
“There will be multi-billion dollar companies that will figure out how to measure those efficiently, deliver that information to the patient, and get feedback from the patient.”
Kaganovich: Researchers distrust public genomic databases because submission standards vary wildly
“But no one trusts other people's submissions, we found, because the standards are different.”
Kaganovich: Genetics is undergoing a horizontalization phase similar to early microprocessors
“The way we kind of see it is that, that, that inflection point has already happened. It's somewhat akin to the microprocessor that forced a lot of horizontalization, de-aggregation of the industry. I think that's happening in genetics”
Kaganovich: Genomics infrastructure requires a Waze-like real-time patient feedback system
“If the human genome was quote unquote mapped in 2000, I think there's kind of one still needs to make the Google Maps of that, and then one after that we would need to make the ways, ah, of the human genome, where you actually have feedback, where you know som…”
Kaganovich: 23andMe's data monetization succeeded because of proper rare variant consents
“23 and Me did an enormous deal with, from data that they had. The reason it was valuable was because they had all the proper consents for this fairly rare collection of variants and clinical data associated with it.”